Clinical trials: Acute Gastrointestinal Graft-versus-host Disease
Leukemia, Graft-Versus-Host Disease
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
The purpose of this study is to determine whether orale budesonide is effective in the prevention of acute gastrointestinal graft-versus-host disease (GVHD) following allogenic stem cell transplantation.
- Trial name
- NCT00180089
- Testing
- Budesonide
- Where
- Germany
- Volunteers
- 242 people
- Sponsor
- Technische Universität Dresden
Endocytoscopy
Endocytoscopy of Upper Gastrointestinal Tract in Acute Graft-versus-host Disease: a Pilot Study
The goal of this clinical trial is to test the assess the diagnostic effectiveness of endocytoscopy in patients with underlying UGI aGvHD. The main question it aims to answer is: the effectiveness of ECS for diagnosing UGI aGvHD.
- Trial name
- NCT06247891
- Testing
- ECS Group
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Ruijin Hospital
Acute Gastrointestinal Graft-versus-host Disease
Prospective Randomized Controlled Study: Amimaitosai Injection Combined With Corticosteroids for Gastrointestinal aGVHD
This study focuses on patients with gastrointestinal-dominant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07803978
- Testing
- Amimaitosai injection, Methylprednisolone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Graft vs Host Disease
Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for various hematologic diseases. However, one of the major challenges of allo-HSCT is the occurrence of graft-versus-host disease (GvHD)…
- Trial name
- NCT07364617
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Chang Gung Memorial Hospital
Mucositis, Graft-versus-host Disease
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
A comparative trial where all patients will receive daily doses of tacrolimus (TAC) until day +60 when tapering will begin, in the absence of graft-versus-host disease (GVHD), and discontinued by day +180.
- Trial name
- NCT00360685
- Testing
- Tac+MTX, TAC + MMF
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Hepatitis C
Australian Trial in Acute Hepatitis C Recall Study
A single long-term follow up assessment of an established multi-centre, prospective longitudinal cohort study of patients for clinical, psychosocial, immunovirological outcomes 4 to 8 years after previous treatment for recently…
- Trial name
- ATAHC Recall (NCT02000063)
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Kirby Institute
Hematopoietic and Lymphoid Cell Neoplasm
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).
- Trial name
- FEMITGIGVHD (NCT03812705)
- Testing
- fecal microbiome transplantation
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Graft Vs Host Disease, Gastrointestinal Graft-Versus-Host Disease
Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD
Patients with gastrointestinal graft-vs.-host disease are randomized to oral beclomethasone dipropionate (BDP) 8 mg/day or identical placebo tablets for 50 days, along with a 10-day induction course of prednisone.
- Trial name
- NCT00233896
- Testing
- Oral beclomethasone dipropionate (drug)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Enteron Pharmaceuticals
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation. This Program is available for female and male who are recipients of allogenic HSCT and who have been newly…
- Conditions
- Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease, Graft Vs Host Disease
- Trial name
- NCT03172455
- Testing
- Glassia
- Sponsor
- Impatients N.V. trading as myTomorrows
Pancreatitis, Chronic, Pancreatitis, Acute
Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
The investigators will enroll a total of 628 patients under 18 years of age with ARP or CP. Included in the total are the 357patients in the INSPPIRE 1 database who are planned to be reenrolled under this protocol over the next 4…
- Trial name
- INSPPIRE 2 (NCT03672422)
- Testing
- Blood sample, Patient questionnaires, Saliva sample
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 623 people
- Sponsor
- Aliye Uc
Graft-versus-host Disease Prevention
Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics.
- Trial name
- NCT03862079
- Testing
- Best Practice, Fecal Microbiota Transplantation, Nystatin
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple
AI Assisted Detection of Chest X-Rays
This study has been added as a sub study to the Simulation Training for Emergency Department Imaging 2 study (ClinicalTrials.gov ID NCT05427838).
- Conditions
- Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple, Pulmonary Consolidation, Pneumothorax
- Trial name
- AID-CXR (NCT06075836)
- Testing
- Cases reading, Ground truthing
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Oxford University Hospitals NHS Trust
GVHD
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
- Trial name
- NCT05415410
- Testing
- Apraglutide
- Where
- 13 sites in United States, Germany and 2 more
- Volunteers
- 31 people
- Sponsor
- VectivBio AG
Acute Graft Versus Host Disease
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.
- Trial name
- NCT00038792
- Testing
- Recombinant Human Keratinocyte Growth Factor
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center